The potential economic impact of the 21-gene recurrence score–guided chemotherapy in a population-based cohort with node-negative and node-positive early-stage breast cancer.
N. W. Lamond
No relevant relationships to disclose
C. Skedgel
No relevant relationships to disclose
D. Rayson
No relevant relationships to disclose
L. Lethbridge
No relevant relationships to disclose
T. Younis
No relevant relationships to disclose